KRYS SEC Filings: 8-K, 10-Q, S-3 & 424B – Krystal Biotech

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 2, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 3, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 4, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Feb 17, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 3, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 4, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Krystal Biotech Reports Third Quarter 2026 Financial Results and Business Updates

Nov 2, 2026

8-K

Krystal Biotech Announces Positive Clinical Data for KB113 in Gorlin Syndrome

Oct 15, 2026

8-K

Krystal Biotech Reports Second Quarter 2026 Financial Results and Business Updates

Aug 3, 2026

8-K

Krystal Biotech Discloses Clinical Observation for KB801 in Patent Filing

Jul 21, 2026

8-K

Krystal Biotech, Inc. Announces Results of 2026 Annual Meeting of Stockholders

May 19, 2026

8-K

Krystal Biotech Reports First Quarter 2026 Financial Results and Pipeline Progress

May 4, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

$150,000,000 Common Stock PROSPECTUS SUPPLEMENT TD Cowen May 8, 2023

May 8, 2023

424B2

2,666,667 Shares

Dec 1, 2021

424B5

Common Stock-

Nov 29, 2021

424B2

1,923,077 Shares

Feb 3, 2021

424B5

Common Stock-

Feb 2, 2021

424B5

Common Stock-

Dec 31, 2020

Registrations

TYPE

HEADLINE

FILED AT

S-8

Registration

Feb 26, 2024

S-3ASR

Common Stock

Jul 18, 2023

S-3ASR

Common Stock

Apr 6, 2023

S-8

Registration

Feb 2, 2023

S-8

Registration

Feb 17, 2022

S-8

Registration

Jan 22, 2021

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 3, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 3, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 3, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 3, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 4, 2024

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 4, 2024

Ownerships

TYPE

HEADLINE

FILED AT

SCHEDULE 13G/A

VANGUARD PORTFOLIO MANAGEMENT LLC (Filed by)

Oct 30, 2026

SCHEDULE 13G/A

BlackRock, Inc. (Filed by)

Oct 27, 2026

ROSSI DINO A (Reporting)

Sep 16, 2026

Sutherland Everett Rand (Reporting)

Sep 16, 2026

Mazzacco Catherine (Reporting)

Sep 16, 2026

Mason Christopher (Reporting)

Sep 16, 2026

Other

TYPE

HEADLINE

FILED AT

LETTER

Form UPLOAD - SEC-generated letter

Apr 24, 2023

CORRESP

Form CORRESP - Correspondence

Apr 11, 2023

LETTER

Form UPLOAD - SEC-generated letter

Mar 30, 2023

EFFECT

Form EFFECT - Notice of Effectiveness

Oct 15, 2018

LETTER

Form UPLOAD - SEC-generated letter

Oct 10, 2018

CORRESP

Form CORRESP - Correspondence

Oct 9, 2018

Krystal Biotech, Inc. KRYS · SEC Filings